Nama's AI scorecard currently rates DENTSPLY SIRONA Sell (4.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is XRAY's P/E ratio?

DENTSPLY SIRONA trades at a trailing price-to-earnings ratio of 7.0.

When does XRAY report earnings?

DENTSPLY SIRONA's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.31.

What is the XRAY price target?

The median analyst price target from 15 analysts is $12.00, with a range of $9.00 – $17.00.

Is XRAY Shariah compliant?

Nama's AAOIFI-style screen reads DENTSPLY SIRONA as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

DENTSPLY SIRONA (XRAY)

Healthcare · Medical Instruments Supplies · NASDAQ

DENTSPLY SIRONA (XRAY) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $1.89B, a trailing price-to-earnings ratio of 7.0 and a free-cash-flow yield of 5.5%. Over the most recent reported fiscal year, revenue declined 3.0% and free cash flow per share fell 62.3%. Nama's AI scorecard rates it Sell, 4.0 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Sell · 4.0/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Trailing · -22.5% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-83.9%

How far the last close sits under the highest price of the past five years.

Market cap	$1.89B
Trailing P/E	7.0
Price / book	1.4
Price / sales	0.5
FCF yield	5.5%
Dividend yield	—
Gross margin	49.5%
Operating margin	5.0%
Net margin	-15.0%
Revenue growth (YoY)	-3.0%
Revenue growth (3-yr annual)	-2.1%
EPS growth (YoY)	-4.8%
FCF/share growth (YoY)	-62.3%
Beta	0.9
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Instruments Supplies

XRAY earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.31). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.29	$0.31	-6.5%	—
Q2 2026	Aug 6, 2026	$0.52	$0.35	+48.6%	$898.00M
Q1 2026	May 5, 2026	$0.27	$0.27	+0.0%	$880.00M
Q4 2025	Feb 26, 2026	$0.27	$0.29	-6.9%	$961.00M

XRAY analyst price target

Median target $12.00 from 15 analysts, ranging $9.00 – $17.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
MDLN	Medline	$52.17B	25.1
ALC	Alcon	$36.23B	23.0
RMD	ResMed	$33.10B	20.4
WST	West Pharmaceutical Services	$27.85B	43.5
SOLV	Solventum	$15.38B	12.8
BAX	Baxter International	$13.34B	13.3

Explore live XRAY data on Nama Insights →

Recent Congressional trades

DENTSPLY SIRONA trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Feb 11, 2025
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Feb 11, 2025
Angus S King, Jr.	Senate	Sell	$1,001 - $15,000	—

XRAY FAQ

Is XRAY a buy?: Nama's AI scorecard currently rates DENTSPLY SIRONA Sell (4.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is XRAY's P/E ratio?: DENTSPLY SIRONA trades at a trailing price-to-earnings ratio of 7.0.
When does XRAY report earnings?: DENTSPLY SIRONA's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.31.
What is the XRAY price target?: The median analyst price target from 15 analysts is $12.00, with a range of $9.00 – $17.00.
Is XRAY Shariah compliant?: Nama's AAOIFI-style screen reads DENTSPLY SIRONA as Not Shariah Compliant. At least one of the three ratios or the industry test failed.